Inetetamab is named as a drug or biological intervention in 3 clinical trials in our China trial register, 2 of which are recruiting. Lead sponsors include Wang Ouchen (1), Peking Union Medical College (1) and Fudan University (1). Registered phases: Not applicable, Phase 3 and Phase 2. Conditions studied include Breast Neoplasm Female; Breast Cancer; HER2-positive, Unresectable, Locally Advanced or Metastatic Breast Cancer.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07182721 | SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment (ClinicalTrials.gov ↗) HER2-positive, Unresectable, Locally Advanced or Metastatic Breast Cancer, SKB264, Inetetamab |
Phase 2 | Recruiting |
| NCT06234137 | A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer (ClinicalTrials.gov ↗) Breast Neoplasm Female |
Not applicable | Recruiting |
| NCT04736589 | Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway (ClinicalTrials.gov ↗) Breast Cancer |
Phase 3 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Breast Neoplasm Female | 1 |
| Breast Cancer | 1 |
| HER2-positive, Unresectable, Locally Advanced or Metastatic Breast Cancer | 1 |
| SKB264 | 1 |
| Inetetamab | 1 |
| Lead sponsor | Trials |
|---|---|
| Wang Ouchen | 1 |
| Peking Union Medical College | 1 |
| Fudan University | 1 |
| Register | Inetetamab trials |
|---|---|
| Clinical trials in China | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Inetetamab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Inetetamab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.